March 11th 2025
Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
February 20th 2025
How Uncertainty & Distrust Damage Relationships with Patients
February 11th 2025In this Pharmaceutical Executive video interview, Ian Baer, Founder & CEO of Sooth, identifies how uncertainty of where to find information, coupled with distrust, can damage the relationship between pharmaceutical companies and the patients they aim to serve.
Quantifying the Benefits of AI-Powered Patient Adherence Programs
December 9th 2024In this part of his Pharmaceutical Executive video interview, Bill Grambley, CEO of AllazoHealth, identifies which metrics and KPIs can be used to measure the effectiveness of AI-powered patient engagement and adherence programs.
How Can Pharma Navigate the Regulatory Maze of AI-Powered Interventions?
December 6th 2024In this part of his Pharmaceutical Executive video interview, Bill Grambley, CEO of AllazoHealth, discusses how pharmaceutical companies navigate the evolving regulatory landscape to ensure that AI-powered interventions comply with relevant regulations and guidelines.
Personalized AI-Powered Solutions for Better Patient Adherence
December 4th 2024In this part of his Pharmaceutical Executive video interview, Bill Grambley, CEO of AllazoHealth, identifies how AI can identify patients at risk of medication non-adherence and intervene early to prevent negative outcomes.
Using AI to Predict and Influence Patient Behavior
December 3rd 2024In this part of his Pharmaceutical Executive video interview, Bill Grambley, CEO of AllazoHealth, explains how AI can be leveraged to create highly personalized patient engagement strategies, tailored to individual needs and preferences.
Delivery and Disruption: Navigating a Changing Care Terrain
September 16th 2024The diversification of site-of-care delivery models is accelerating rapidly, creating new go-to-market implications for drug manufacturers—but also new opportunities to drive more fundamental innovation in engagement and access strategies.
Pharm Exec Exclusive: Mark Cuban Talks Drug Pricing
June 7th 2024Now more than two years into launching his alternative and transparent drug payment model, the longtime entrepreneur, in an interview with Pharm Exec, discusses the prescription drug cost landscape and shares his recipe for true disruption to the pharma pricing machine.